Teva (TEVA) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Teva, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track TEVA live on Mooboard →

31–90 days3

  • Sep 15, 2026
    Teva(TEVA)Phase 2/3 readout
    TEV-53408 · Phase 2 · Celiac Disease
    NCT06807463: A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease. Primary completion 2026-09-15 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 19, 2026
    Teva(TEVA)Phase 2/3 readout
    Fp/ABS · Phase 3 · Asthma
    NCT06664619: A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma. Primary completion 2026-09-19 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Oct 31, 2026
    Teva(TEVA)Phase 2/3 readout
    TEV-56248 · Phase 3 · Asthma
    NCT06052267: A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations. Primary completion 2026-10-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗

Later2

  • Sep 15, 2027
    Teva(TEVA)Phase 2/3 readout
    TEV-56286 · Phase 2 · Multiple System Atrophy
    NCT06568237: A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy. Primary completion 2027-09-15 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 3, 2029
    Teva(TEVA)Phase 2/3 readout
    TEV-56286 · Phase 2 · Multiple System Atrophy
    NCT07197866: An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy. Primary completion 2029-05-03 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Teva has moved — past-year price reactions

How binary is TEVA? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.1%
typical day (1Y)
2
±10% days
40.2%
annualized vol
250
trading days
Largest single-day moves
  • +20.2%2025-11-05no matched headline
  • +11.9%2026-04-29no matched headline
  • +9.6%2026-07-29no matched headline
  • +6.8%2025-08-21no matched headline
  • +6.2%2026-03-31no matched headline
  • +5.3%2025-11-26no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Teva — active clinical pipeline

Teva's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

7 assets8 programsPh1 3Ph2 3Ph3 2
AreasOncologyAutoimmuneImmunologyOther
Fp/ABSImmunology
Phase 3
Asthma
TEV-56248Immunology
Phase 3
Asthma
TEV-53408Autoimmune
Phase 1
Vitiligo
Phase 2
Celiac Disease
TEV-48574 Dose Regimen AAutoimmune
Phase 2
Crohn Disease
TEV-56286Autoimmune
Phase 2
Multiple System Atrophy (2)
TEV-56278Oncology
Phase 1
Advanced Solid Tumors
TEV-56286 Dose AOther
Phase 1
Healthy volunteers

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.